This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FLXN Flexion Therapeutics (FLXN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsSustainabilityTrendsBuy This Stock About Flexion Therapeutics Stock (NASDAQ:FLXN) 30 days 90 days 365 days Advanced Chart Get Flexion Therapeutics alerts:Sign Up Key Stats Today's Range$25.33▼$25.3850-Day Range$9.12▼$9.4452-Week Range$4.30▼$13.66Volume1,020 shsAverage Volume1.18 million shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. Read More Receive FLXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Flexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FLXN Stock News HeadlinesFlexion wins contract to support CFPB in evaluating financial education contentApril 25, 2024 | finance.yahoo.comFlexion awarded contract to revolutionize Head Start’s Data Management SystemApril 19, 2024 | finance.yahoo.comSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split the entire U.S. market in two on or before Sept 30, causing a crisis "many times worse than 2008."August 30 at 2:00 AM | Altimetry (Ad)Flexion Joins AWS Public Sector Partner Program, Enhancing Commitment to Public Sector Software ProjectsApril 11, 2024 | tmcnet.comVIRI Virios Therapeutics, Inc.April 6, 2024 | seekingalpha.comSpyre Therapeutics Inc SYREFebruary 14, 2024 | morningstar.comMPFIZER INC's Net WorthFebruary 10, 2024 | benzinga.comSpringWorks Therapeutics Stock (NASDAQ:SWTX), Analyst Ratings, Price Targets, PredictionsNovember 24, 2023 | benzinga.comSee More Headlines FLXN Stock Analysis - Frequently Asked Questions How were Flexion Therapeutics' earnings last quarter? Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced its quarterly earnings results on Wednesday, May, 12th. The specialty pharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.08. The specialty pharmaceutical company earned $24.59 million during the quarter, compared to analyst estimates of $24.61 million. What other stocks do shareholders of Flexion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), NVIDIA (NVDA), Gilead Sciences (GILD), Bristol Myers Squibb (BMY), Lipocine (LPCN), Micron Technology (MU) and Viking Therapeutics (VKTX). Company Calendar Last Earnings5/12/2021Today8/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FLXN CIK1419600 Webwww.flexiontherapeutics.com Phone(781) 305-7777Fax781-202-3399Employees257Year Founded2007Profitability EPS (Trailing Twelve Months)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$113.71 million Net Margins-100.32% Pretax Margin-100.32% Return on EquityN/A Return on Assets-44.26% Debt Debt-to-Equity RatioN/A Current Ratio4.38 Quick Ratio4.05 Sales & Book Value Annual Sales$85.55 million Price / Sales14.90 Cash FlowN/A Price / Cash FlowN/A Book Value($0.34) per share Price / Book-74.51Miscellaneous Outstanding Shares50,321,000Free Float45,727,000Market Cap$1.27 billion OptionableNo Data Beta1.53 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:FLXN) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flexion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Flexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
